On April 27, 2025, at the achievements release event for the Qianhai Shekou Free Trade Zone in Shenzhen, Deep Harbour Cell Valley (Shenzhen) Medical Technology Co., Ltd. was honored with the "Top Ten Key Investment Projects of the China (Guangdong) Pilot Free Trade Zone Shenzhen Qianhai Shekou Area" award. Professor Shi Yuanyuan, the company's founder, attended the event as a representative of key enterprises and shared the strategic development plans for Deep Harbour Cell Valley within the Qianhai area.

In an interview, Professor Shi stated that the pilot policy jointly issued by three national ministries and commissions is groundbreaking, as it permits foreign-funded enterprises to conduct R&D and applications of technologies related to human stem cells, gene diagnosis, and therapy within the pilot free trade zone for the first time, opening up a new track for the industry. As one of the first enterprises in the Guangdong Pilot Free Trade Zone to benefit from this national medical opening-up policy, Deep Harbour Cell Valley will use Qianhai as a strategic pivot. Focusing on the internationally cutting-edge field of cell and gene therapy, the company aims to actively build a Shenzhen-Hong Kong collaborative innovation mechanism and promote a new development model of deep integration between healthcare and industry.Leveraging the core technological expertise of the Cell Valley Group in cell therapy, and with its unique industrial-scale production of retroviral vector technology as its core competency, the company will establish a full-industry-chain platform covering R&D, production, and medical services. Professor Shi emphasized that Qianhai's al advantage, being just "a bridge away" from Hong Kong, provides natural convenience for the company to efficiently connect with international capital and attract global clients. Furthermore, the full-process support from the Qianhai Administration, offering precise assistance in everything from registration and site selection to talent support and tax/customs clearance, helped the company complete its setup in just three months. Operations are expected to officially commence in May 2025.

Deep Harbour Cell Valley is positioned as the international business and medical services headquarters for the Cell Valley Group. It will serve the Guangdong-Hong Kong-Macao Greater Bay Area, Southeast Asia, and the Americas with high-end cell and gene therapy solutions. Simultaneously, it will enter consumer healthcare sectors such as wellness and medical aesthetics, creating an innovative "medical + consumer" dual-drive model. Currently, Deep Harbour Cell Valley is collaborating with the Hong Kong Hospital Authority and other medical institutions to establish a cell product preparation and scientific research transformation platform. The company also plans to gradually enter the medical aesthetics and anti-aging fields, developing precise health management services for the consumer market. Leveraging Qianhai's cross-border service advantages, it will also extend its reach to overseas markets by providing technology export and high-end medical services.